ALK Human siRNA Oligo Duplex (Locus ID 238)
CAT#: SR300165
ALK (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each
Need single siRNA in bulk?
Get a free quote
CNY 4,090.00
货期*
4周
规格
Cited in 2 publications. |
Product images
![](https://cdn.origene.com/img/defaults-img.jpg)
经常一起买 (3)
Specifications
Product Data | |
Purity | HPLC purified |
Quality Control | Tested by ESI-MS |
Sequences | Available with shipment |
Stability | One year from date of shipment when stored at -20°C. |
# of transfections | Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM). |
Note | Single siRNA duplex (10nmol) can be ordered. |
Reference Data | |
RefSeq | NM_004304, NM_001353765 |
Synonyms | CD246; NBLST3 |
Components | ALK (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 238)Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmolIncluded - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml |
Summary | This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQSTM1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011] |
Performance Guranteed | OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency. For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required). |
Citations (2)
The use of this RNAi has been cited in the following citations: |
---|
Targeting ALK in pediatric RMS does not induce antitumor activity in vivo
,Wierdl, M;Tsurkan, L;Chi, L;Hatfield, MJ;Tollemar, V;Bradley, C;Chen, X;Qu, C;Potter, PM;,
Cancer Chemother. Pharmacol.
,PubMed ID 29855693
[ALK]
|
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma
,Wood, AC;Krytska, K;Ryles, HT;Infarinato, NR;Sano, R;Hansel, TD;Hart, LS;King, FJ;Smith, TR;Ainscow, E;Grandinetti, KB;Tuntland, T;Kim, S;Caponigro, G;He, YQ;Krupa, S;Li, N;Harris, JL;Mossé, YP;,
Clin. Cancer Res.
,PubMed ID 27986745
[ALK]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...